Recursion Pharmaceuticals (RXRX) Competitors $4.84 +0.07 (+1.47%) Closing price 04:00 PM EasternExtended Trading$4.84 +0.00 (+0.10%) As of 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RXRX vs. RVMD, RYTM, GRFS, ABVX, LEGN, RNA, AXSM, CYTK, NUVL, and TGTXShould you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Revolution Medicines (RVMD), Rhythm Pharmaceuticals (RYTM), Grifols (GRFS), Abivax (ABVX), Legend Biotech (LEGN), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Cytokinetics (CYTK), Nuvalent (NUVL), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Recursion Pharmaceuticals vs. Its Competitors Revolution Medicines Rhythm Pharmaceuticals Grifols Abivax Legend Biotech Avidity Biosciences Axsome Therapeutics Cytokinetics Nuvalent TG Therapeutics Recursion Pharmaceuticals (NASDAQ:RXRX) and Revolution Medicines (NASDAQ:RVMD) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings. Does the media prefer RXRX or RVMD? In the previous week, Revolution Medicines had 37 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 49 mentions for Revolution Medicines and 12 mentions for Recursion Pharmaceuticals. Recursion Pharmaceuticals' average media sentiment score of 0.80 beat Revolution Medicines' score of 0.41 indicating that Recursion Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Recursion Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 15 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend RXRX or RVMD? Recursion Pharmaceuticals presently has a consensus target price of $7.25, indicating a potential upside of 49.79%. Revolution Medicines has a consensus target price of $73.67, indicating a potential upside of 64.80%. Given Revolution Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Revolution Medicines is more favorable than Recursion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Recursion Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Revolution Medicines 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 Is RXRX or RVMD more profitable? Revolution Medicines has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -1,004.91%. Revolution Medicines' return on equity of -41.78% beat Recursion Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Recursion Pharmaceuticals-1,004.91% -76.09% -54.29% Revolution Medicines N/A -41.78%-35.63% Do institutionals & insiders have more ownership in RXRX or RVMD? 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 8.2% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has stronger valuation & earnings, RXRX or RVMD? Recursion Pharmaceuticals has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRecursion Pharmaceuticals$58.84M35.71-$463.66M-$1.78-2.72Revolution MedicinesN/AN/A-$600.09M-$4.50-9.93 Which has more risk and volatility, RXRX or RVMD? Recursion Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Revolution Medicines has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500. SummaryRevolution Medicines beats Recursion Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Get Recursion Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RXRX vs. The Competition Export to ExcelMetricRecursion PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.10B$2.50B$5.70B$10.26BDividend YieldN/A57.22%5.72%4.60%P/E Ratio-2.7223.1675.8826.53Price / Sales35.71527.70492.67165.78Price / CashN/A27.5625.8129.90Price / Book1.855.2612.836.32Net Income-$463.66M$32.95M$3.28B$270.12M7 Day Performance2.98%-0.55%0.17%2.12%1 Month Performance-16.12%3.79%4.54%6.31%1 Year Performance-27.22%-3.14%68.32%25.51% Recursion Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RXRXRecursion Pharmaceuticals2.3 of 5 stars$4.84+1.5%$7.25+49.8%-27.4%$2.10B$58.84M-2.72400RVMDRevolution Medicines4.2613 of 5 stars$40.50+4.0%$72.00+77.8%+5.7%$7.28B$11.58M-9.00250Insider TradeAnalyst RevisionRYTMRhythm Pharmaceuticals3.3207 of 5 stars$102.12-2.3%$101.57-0.5%+93.5%$6.95B$130.13M-33.93140Positive NewsGRFSGrifols3.8816 of 5 stars$10.13+2.3%$10.30+1.7%+4.0%$6.81B$7.81B8.6623,822Gap UpABVXAbivax2.7344 of 5 stars$88.03+2.9%$92.33+4.9%+632.7%$6.47BN/A0.0061Analyst UpgradeShort Interest ↑High Trading VolumeLEGNLegend Biotech3.1912 of 5 stars$36.08+3.1%$74.22+105.7%-32.7%$6.46B$627.24M-41.002,609Positive NewsRNAAvidity Biosciences2.0957 of 5 stars$50.36+3.9%$67.00+33.0%-3.6%$6.24B$10.73M-14.15190Analyst ForecastHigh Trading VolumeAXSMAxsome Therapeutics4.8829 of 5 stars$125.17+0.6%$177.86+42.1%+24.7%$6.21B$385.69M-24.69380Positive NewsCYTKCytokinetics4.3674 of 5 stars$53.01+6.6%$75.38+42.2%-11.5%$5.95B$18.47M-10.39250Positive NewsInsider TradeNUVLNuvalent3.1557 of 5 stars$80.89+1.5%$120.91+49.5%-9.2%$5.74BN/A-16.5140Positive NewsTGTXTG Therapeutics4.2954 of 5 stars$32.21+1.0%$46.25+43.6%+33.8%$5.06B$329M87.05290Positive News Related Companies and Tools Related Companies Revolution Medicines Competitors Rhythm Pharmaceuticals Competitors Grifols Competitors Abivax Competitors Legend Biotech Competitors Avidity Biosciences Competitors Axsome Therapeutics Competitors Cytokinetics Competitors Nuvalent Competitors TG Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RXRX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXRX Stock Alerts